Product Information
PREGABALIN ER 330 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $2.1242 per EA under NDC 72888005130. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Mar 22, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Pregabalin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
330 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888005130
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA215249FDA Approved
3/22/2022
TE Code
AB
On Market Since
3/22/2022
Price Statistics
The NADAC for PREGABALIN ER 330 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 33.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1242 per EA |
|---|---|
| All-time high | $3.9513 (Sep 11, 2024) |
| All-time low | $2.1193 (Aug 19, 2026) |
| 52-week high | $3.7250 |
| 52-week low | $2.1193 |
| Median price | $3.3586 |
| Average price | $3.2459 |
| Largest weekly change | -14.4% (Aug 19, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Pregabalin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pregabalin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN ER 330 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN ER 330 MG TABLET, manufactured by Advagen Pharma Ltd., is $2.1242 per EA (NDC 72888005130), effective Sep 30, 2026.
How has the price of PREGABALIN ER 330 MG TABLET changed over time?
Over the history we have for it, the NADAC for PREGABALIN ER 330 MG TABLET has declined 33.9%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for PREGABALIN ER 330 MG TABLET?
Since Apr 17, 2024, the NADAC for PREGABALIN ER 330 MG TABLET has ranged from a low of $2.1193 (Aug 19, 2026) to a high of $3.9513 (Sep 11, 2024), with a median of $3.3586 per EA.
Are there cheaper alternatives to PREGABALIN ER 330 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PREGABALIN ER 330 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PREGABALIN ER 330 MG TABLET?
PREGABALIN ER 330 MG TABLET (NDC 72888005130) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.